key: cord-0874487-01asvwoe
authors: Kaura, Vikas; Hopkins, Philip M.
title: Sevoflurane may not be a complete sigh of relief in COVID-19
date: 2020-09-16
journal: Br J Anaesth
DOI: 10.1016/j.bja.2020.09.012
sha: 86221adeb6f5731c30dab95f28ab1e892f1e1639
doc_id: 874487
cord_uid: 01asvwoe

nan

*Corresponding author. Email: vkaura@doctors.org.uk @vikaskaura1 Keywords: COVID-19, ICU, malignant hyperthermia, sedation, sevoflurane, volatile anaesthetics Editor -We read with interest the editorial by Nieuwenhuijs-Moeke and colleagues 1 on the use of sevoflurane as an Intensive care unit (ICU) sedative in patients admitted with COVID-19. We were surprised that there was no mention of the potential for a fatal episode of malignant hyperthermia (MH) when using a volatile anaesthetic agent as a sedative in the ICU. Although rare, cases of MH triggered in the ICU do occur. 2 Unpublished data from the UK MH unit in Leeds show that there have been two patients referred in the past five years following an MH episode as a result of exposure to a volatile anaesthetic agent in the ICU: in both cases the volatile anaesthetic was used to alleviate status asthmaticus. In one case the volatile anaesthetic was isoflurane and in the other, sevoflurane. As reported 3 , sevoflurane is now the most common triggering agent in new cases referred to the UK MH unit, supplanting isoflurane. However isoflurane remains the most common triggering agent over the last 30 years.

We do not suggest that the possibility of an MH reaction should be the overriding factor in the choice of ICU sedative, but use of volatile anaesthetics in this setting should be J o u r n a l P r e -p r o o f accompanied by education of ICU staff in the recognition and management of an MH reaction 4 . Display of visual aids for diagnosis and management in the relevant bed-space might also be considered (these can be downloaded from www.ukmhr.ac.uk). Furthermore, it should be noted that an MH reaction within the ICU may be more difficult to diagnose than in the operating theatre because of a high incidence of conditions that are associated with clinical features of MH (hypercarbia, tachycardia, raised temperature, hypoxaemia, acidosis, hyperkalaemia 4 ), such as sepsis, respiratory failure, or acute kidney injury: these clinical features are also frequently observed in critically ill patients with COVID-19. 5 Also adequate stocks of dantrolene 6 and activated charcoal filters 7 should be available.

Population genome and exome sequencing projects have revealed the high population incidence (1:1500) of genetic variants associated with susceptibility to MH. 8 It is likely that there are genetic and non-genetic factors contributing to the discrepancy between the prevalence of such genetic variants and the incidence of clinical MH 9 , but these are unknown. It is possible that the non-genetic contributors to triggering may be more common in critically ill patients, so while the current low incidence of MH in the ICU setting is likely to reflect the infrequent use of volatile anaesthetic sedation, an increase in this practice may reveal that critically ill MH susceptible patients have a greater chance of triggering than in the operating theatre.

As volatile anaesthtic sedation becomes more prevalent, intensivists and ICU nurses should be added to anaesthetists, pre-hospital practitioners and emergency room physicians in the list of practitioners who need to be explicitly aware that MH reactions still occur, and can be triggered by use of any of the volatile anaesthetic agents, including methoxyflurane 10 , and by the depolarising muscle relaxant succinylcholine. 4 

Malignant hyperthermia in the intensive care setting

Has malignant hyperthermia really disappeared with halothane?

Diagnosis and management of malignant hyperthermia

Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations

Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines

The use of charcoal filters in malignant hyperthermia: Have they found their place?

Genomic Screening for Malignant Hyperthermia Susceptibility

Mission impossible or mission futile? Estimating penetrance for malignant hyperthermia

A review of the safety and efficacy of inhaled methoxyflurane as an analgesic for outpatient procedures